Century Therapeutics, Inc. Short-term Lease, Cost
Century Therapeutics, Inc. (IPSC) reported Short-term Lease, Cost of $906.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ShortTermLeaseCost · last filed 2025-03-19
- Century Therapeutics, Inc. short-term lease, cost for the quarter ending 2023-12-31 was $5.00K, a 99.21% decline year-over-year.
- Century Therapeutics, Inc. short-term lease, cost for the quarter ending 2023-09-30 was $5.00K, a 99.17% decline year-over-year.
- Century Therapeutics, Inc. short-term lease, cost for the quarter ending 2023-06-30 was $302.00K, a 58.06% decline year-over-year.
- Century Therapeutics, Inc. short-term lease, cost for the quarter ending 2023-03-31 was $594.00K, a 8.47% decline year-over-year.
- Century Therapeutics, Inc. short-term lease, cost for fiscal 2023 was $906.00K, a 65.15% decline from fiscal 2022.
- Century Therapeutics, Inc. short-term lease, cost for fiscal 2022 was $2.60M, a 1.07% decline from fiscal 2021.
- Century Therapeutics, Inc. short-term lease, cost for fiscal 2021 was $2.63M, a 11.73% increase from fiscal 2020.
- Century Therapeutics, Inc. short-term lease, cost for fiscal 2020 was $2.35M.
| Period end | Short-term Lease, Cost 3 month | Short-term Lease, Cost 6 month | Short-term Lease, Cost 9 month | Short-term Lease, Cost 12 month |
|---|---|---|---|---|
| 2023-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $10.00K derived: sum of 2 quarters · filed 2025-03-19 | $312.00K derived: sum of 3 quarters · filed 2025-03-19 | $906.00K 10-K · filed 2025-03-19 |
| 2023-09-30 | $5.00K 10-Q · filed 2024-11-05 | $307.00K derived: sum of 2 quarters · filed 2024-11-05 | $901.00K 10-Q · filed 2024-11-05 | $1.53M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $302.00K 10-Q · filed 2024-08-08 | $896.00K 10-Q · filed 2024-08-08 | $1.52M derived: sum of 3 quarters · filed 2024-08-08 | $2.13M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $594.00K 10-Q · filed 2024-05-09 | $1.22M derived: sum of 2 quarters · filed 2024-05-09 | $1.82M derived: sum of 3 quarters · filed 2024-05-09 | $2.54M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $629.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $1.23M derived: sum of 2 quarters · filed 2024-03-14 | $1.95M derived: sum of 3 quarters · filed 2024-03-14 | $2.60M 10-K · filed 2024-03-14 |
| 2022-09-30 | $602.00K 10-Q · filed 2023-11-09 | $1.32M derived: sum of 2 quarters · filed 2023-11-09 | $1.97M 10-Q · filed 2023-11-09 | $2.64M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $720.00K 10-Q · filed 2023-08-09 | $1.37M 10-Q · filed 2023-08-09 | $2.03M derived: sum of 3 quarters · filed 2023-08-09 | $2.69M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $649.00K 10-Q · filed 2023-05-11 | $1.31M derived: sum of 2 quarters · filed 2023-05-11 | $1.97M derived: sum of 3 quarters · filed 2023-05-11 | $2.61M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $665.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $1.32M derived: sum of 2 quarters · filed 2023-03-16 | $1.96M derived: sum of 3 quarters · filed 2023-03-16 | $2.63M 10-K · filed 2023-03-16 |
| 2021-09-30 | $653.00K 10-Q · filed 2022-11-10 | $1.29M derived: sum of 2 quarters · filed 2022-11-10 | $1.96M 10-Q · filed 2022-11-10 | $2.59M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $642.00K 10-Q · filed 2022-08-11 | $1.31M 10-Q · filed 2022-08-11 | $1.93M derived: sum of 3 quarters · filed 2022-08-11 | $2.55M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $668.00K 10-Q · filed 2022-05-16 | $1.29M derived: sum of 2 quarters · filed 2022-05-16 | $1.91M derived: sum of 3 quarters · filed 2022-05-16 | $2.52M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $623.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $1.24M derived: sum of 2 quarters · filed 2022-03-17 | $1.86M derived: sum of 3 quarters · filed 2022-03-17 | $2.35M 10-K · filed 2022-03-17 |
| 2020-09-30 | $620.00K 10-Q · filed 2021-11-10 | $1.23M derived: sum of 2 quarters · filed 2021-11-10 | $1.73M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $613.00K 10-Q · filed 2021-08-12 | $1.11M 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |